Double maintains 4 strategies that include RGEN - Repligen Corp.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FBT | 61.78% | $1.01B | 0.54% |
| GNOM | 60.65% | $44.57M | 0.5% |
| IBB | 59.56% | $5.26B | 0.45% |
| MOAT | 58.20% | $12.66B | 0.47% |
| PBE | 58.14% | $223.19M | 0.58% |
| ARKG | 57.34% | $1.02B | 0.75% |
| SMOT | 57.05% | $387.12M | 0.49% |
| QQQJ | 57.02% | $621.52M | 0.15% |
| BBH | 56.96% | $330.62M | 0.35% |
| VBK | 56.85% | $19.01B | 0.07% |
| XHE | 56.44% | $166.72M | 0.35% |
| TMSL | 56.00% | $828.66M | 0.55% |
| VB | 55.87% | $63.31B | 0.05% |
| XBI | 55.77% | $4.82B | 0.35% |
| MDY | 55.73% | $22.71B | 0.24% |
| IVOG | 55.70% | $1.11B | 0.15% |
| XJH | 55.70% | $286.64M | 0.12% |
| VXF | 55.67% | $22.29B | 0.05% |
| XMHQ | 55.65% | $4.97B | 0.25% |
| IJH | 55.63% | $94.92B | 0.05% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -43.62% | $99.63M | 0.59% |
| VIXY | -40.18% | $164.54M | 0.85% |
| BTAL | -39.06% | $296.22M | 1.43% |
| IVOL | -27.07% | $347.03M | 1.02% |
| FTSD | -19.78% | $231.81M | 0.25% |
| XONE | -19.52% | $625.28M | 0.03% |
| SPTS | -19.24% | $5.80B | 0.03% |
| STPZ | -18.94% | $450.47M | 0.2% |
| TBLL | -17.63% | $2.13B | 0.08% |
| VGSH | -16.62% | $22.80B | 0.03% |
| SCHO | -16.58% | $11.03B | 0.03% |
| UTWO | -16.27% | $379.52M | 0.15% |
| VTIP | -15.68% | $15.33B | 0.03% |
| SHYM | -15.66% | $357.13M | 0.35% |
| IBTH | -14.03% | $1.62B | 0.07% |
| XHLF | -13.91% | $1.73B | 0.03% |
| BILS | -13.81% | $3.81B | 0.1356% |
| TPMN | -13.26% | $30.70M | 0.65% |
| FXY | -13.21% | $816.38M | 0.4% |
| CLIP | -13.21% | $1.51B | 0.07% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -25.34% | $24.23B | +35.36% | 1.09% |
| CME | -24.00% | $99.39B | +40.68% | 3.86% |
| ED | -13.90% | $36.00B | +12.64% | 3.34% |
| MO | -11.63% | $99.67B | +28.77% | 6.90% |
| QXO | -11.55% | $14.47B | -66.08% | 0.00% |
| AWK | -11.08% | $27.36B | +9.65% | 2.21% |
| KMB | -10.24% | $43.92B | -3.75% | 3.75% |
| EXC | -9.78% | $43.33B | +23.58% | 3.62% |
| T | -8.99% | $203.71B | +51.55% | 3.92% |
| KR | -8.67% | $46.43B | +38.38% | 1.85% |
| SO | -8.60% | $100.18B | +17.28% | 3.18% |
| VSTA | -8.27% | $344.07M | +39.29% | 0.00% |
| AEP | -8.11% | $55.16B | +17.93% | 3.54% |
| VZ | -7.72% | $183.79B | +6.01% | 6.18% |
| DUK | -7.46% | $90.99B | +17.25% | 3.56% |
| LITB | -7.36% | $21.24M | -78.57% | 0.00% |
| TEF | -6.29% | $30.08B | +25.41% | 6.16% |
| MKTX | -5.79% | $8.22B | +9.03% | 1.38% |
| CL | -5.61% | $74.88B | -3.64% | 2.19% |
| VSA | -5.23% | $8.67M | -19.04% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CARV | -0.09% | $8.88M | +26.23% | 0.00% |
| COR | -0.21% | $56.44B | +30.86% | 0.74% |
| TU | -0.22% | $24.75B | +7.77% | 7.12% |
| CMS | 0.25% | $20.85B | +18.38% | 3.02% |
| WEC | -0.27% | $33.11B | +33.56% | 3.32% |
| AIFU | 0.29% | $6.79B | +102.19% | 0.00% |
| CNK | 0.33% | $3.47B | +41.29% | 0.53% |
| PM | 0.49% | $273.81B | +73.45% | 3.06% |
| STG | -0.56% | $30.78M | -22.51% | 0.00% |
| CHD | 0.58% | $24.14B | -7.11% | 1.19% |
| LTC | 0.68% | $1.62B | +2.68% | 6.46% |
| KVUE | 0.72% | $40.13B | +14.15% | 3.92% |
| PPC | 0.92% | $10.84B | +33.46% | 0.00% |
| ASPS | 0.96% | $108.30M | -4.13% | 0.00% |
| CI | -1.01% | $85.59B | -1.55% | 1.81% |
| MSEX | 1.01% | $1.00B | +5.97% | 2.41% |
| VIV | 1.12% | $18.81B | +44.82% | 0.66% |
| LTM | 1.22% | $12.63B | -95.46% | 2.42% |
| GORV | 1.27% | $27.07M | -91.17% | 0.00% |
| UFI | 1.30% | $92.35M | -10.82% | 0.00% |
Yahoo
Repligen’s first quarter results for 2025 saw revenue and adjusted profits exceed Wall Street expectations, but the market reacted negatively, reflecting investor caution. Management attributed growth to strong demand across its protein, chromatography, and analytics product lines, as well as robust order momentum in biopharma manufacturing. CEO Olivier Loeillot highlighted that "orders were up high teens year on year with all franchises growing double digits," and noted particularly strong perf
Yahoo
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
SeekingAlpha
Repligen has struggled with falling sales, margin pressure, and a weakened growth outlook, making its premium valuation hard to justify. Learn why RGEN stock is a hold.
Yahoo
The United States market has experienced a steady climb, rising 1.4% in the last week and showing a robust 12% increase over the past year, with earnings projected to grow by 15% annually. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets amidst positive market momentum.
Yahoo
Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.
Yahoo
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FXE | 0.03% | $568.94M | 0.4% |
| BIV | 0.05% | $23.39B | 0.03% |
| TLH | 0.08% | $11.52B | 0.15% |
| TIP | 0.08% | $13.96B | 0.18% |
| AGGH | -0.22% | $324.95M | 0.29% |
| TOTL | -0.22% | $3.84B | 0.55% |
| ISTB | 0.27% | $4.44B | 0.06% |
| HYD | -0.32% | $3.32B | 0.32% |
| SCHQ | 0.41% | $758.74M | 0.03% |
| PZA | 0.45% | $2.84B | 0.28% |
| MEAR | 0.46% | $1.13B | 0.25% |
| UNG | 0.49% | $360.54M | 1.06% |
| XBIL | -0.53% | $783.90M | 0.15% |
| FLCB | -0.56% | $2.61B | 0.15% |
| MBB | 0.77% | $39.33B | 0.04% |
| JPLD | 0.77% | $1.77B | 0.24% |
| UDN | 0.78% | $148.33M | 0.78% |
| LMBS | -0.82% | $5.11B | 0.64% |
| UUP | -0.85% | $201.63M | 0.77% |
| USDU | -0.86% | $162.43M | 0.5% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DHR | 66.58% | $144.92B | -15.63% | 0.58% |
| A | 66.05% | $34.28B | -4.34% | 1.00% |
| BIO | 63.41% | $6.82B | -7.19% | 0.00% |
| TMO | 60.75% | $161.48B | -20.14% | 0.38% |
| MTD | 60.75% | $25.06B | -10.96% | 0.00% |
| BRKR | 60.43% | $6.43B | -31.33% | 0.47% |
| TECH | 60.42% | $8.34B | -25.57% | 0.60% |
| RVTY | 57.74% | $11.89B | -1.62% | 0.28% |
| BLFS | 56.89% | $1.08B | +13.58% | 0.00% |
| IQV | 56.52% | $28.48B | -20.39% | 0.00% |
| SWK | 53.64% | $11.07B | -10.42% | 4.59% |
| IT | 53.46% | $30.44B | -11.68% | 0.00% |
| WAT | 53.42% | $20.94B | +22.41% | 0.00% |
| TXG | 53.14% | $1.62B | -30.61% | 0.00% |
| LFUS | 53.08% | $5.87B | -6.00% | 1.17% |
| TRU | 51.96% | $17.59B | +19.24% | 0.48% |
| AZTA | 51.66% | $1.50B | -36.77% | 0.00% |
| MCHP | 50.94% | $39.46B | -21.82% | 2.45% |
| OC | 49.98% | $12.38B | -13.53% | 1.77% |
| ZBRA | 49.91% | $16.29B | +2.41% | 0.00% |
Current Value
$129.111 Year Return
Current Value
$129.111 Year Return
